Adaptive Biotechnologies to Present clonoSEQ® MRD Assessment Data at 2024 ASCO and EHA Congresses

Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a biotechnology firm focusing on translating the adaptive immune system's genetics into clinical products, announced that their clonoSEQ® test for measurable residual disease (MRD) will be featured in multiple presentations at upcoming medical conferences. These include the American Society of Clinical Oncology (ASCO) Annual Meeting from May 31 to June 4 in Chicago and the European Hematology Association (EHA) Hybrid Congress from June 13 to 16 in Madrid and online.

Susan Bobulsky, Adaptive Biotechnologies' Chief Commercial Officer for MRD, emphasized that the forthcoming data presentations at ASCO and EHA reinforce clonoSEQ's pivotal role in MRD assessment within blood cancer treatments. The clonoSEQ test remains a leading method, providing clinicians with essential insights to guide treatment decisions and aiding drug developers with a reliable tool to advance promising therapies.

MRD status is a crucial indicator of outcomes in blood cancers. Regular MRD testing offers a tailored method to monitor treatment responses, detect early relapse signs, and support shared decision-making for optimal care. In drug development, clonoSEQ is extensively used to evaluate treatment efficacy and has become a primary endpoint in clinical trials.

Key data to be showcased at ASCO and EHA include:

1. Pediatric Acute Lymphoblastic Leukemia (ALL): Research from the Children's Oncology Group highlighted a strong correlation between MRD assessments in bone marrow and peripheral blood using clonoSEQ, suggesting a less invasive monitoring method for ALL patients.

2. Multiple Myeloma (MM): Clinical trial results and real-world evidence demonstrated the importance of sustained MRD negativity and deep response levels in predicting outcomes like overall survival (OS) and progression-free survival (PFS). Findings from the University of Chicago's MRD2STOP study indicated that clonoSEQ might help identify MM patients who can safely discontinue maintenance therapy while maintaining MRD negativity.

3. PERSEUS Study: Conducted in Spain, this study compared MRD negativity in patients treated with bortezomib/lenalidomide/dexamethasone (VRd) with or without daratumumab (D). The results linked deeper MRD responses (10–6) in the D-VRd/D-R regimen with improved PFS.

4. CAR-T Therapies: Multiple trials involving CAR-T cell therapies showed clonoSEQ's utility in measuring deep responses in difficult-to-treat populations, associating MRD negativity with better PFS.

5. Chronic Lymphocytic Leukemia (CLL): Data underscored the use of clonoSEQ in guiding individualized treatment modifications based on MRD status.

Specific presentations at ASCO:
- B-Cell Acute Lymphoblastic Leukemia: Oral Presentation 6504, focusing on the survival and impact of CAR-T cell persistency in relapsed/refractory B-ALL.
- Multiple Myeloma: Various presentations (7505, 7510, 7502) will discuss the efficacy and safety of therapies like ciltacabtagene autoleucel and venetoclax-dexamethasone in MM.

Presentations at EHA will include:
- B-Cell Acute Lymphoblastic Leukemia: Oral Presentation S114, similar to ASCO's 6504.
- Chronic Lymphocytic Leukemia: Oral Presentation S164, focusing on first-line treatment with pirtobrutinib, venetoclax, and obinutuzumab.

Additionally, clonoSEQ data will be presented in various poster sessions at both conferences, covering a range of studies in blood cancers.

About clonoSEQ:
clonoSEQ is the first and only FDA-cleared test for detecting MRD in specific blood cancers, including multiple myeloma, B-cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia. It uses Adaptive Biotechnologies' proprietary platform to quantify malignant cell DNA sequences, providing accurate MRD measurements to predict patient outcomes, assess treatment responses, and monitor disease progression.

Adaptive Biotechnologies aims to harness the adaptive immune system's biology to innovate disease diagnosis and treatment. Their platform supports partnerships with biopharmaceutical companies, driving drug development and clinical diagnostics in areas like cancer and autoimmune disorders.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!